Hematology

Latest News

Multiple Myeloma | Image Credit: © Dzmitry-stock.adobe.com
OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM

November 19th 2024

The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).

Don M. Benson, MD, PhD, James Cancer Hospital
Elevating Myeloma Care Amidst Complex Treatment Choices

November 15th 2024

Genes - CrazyJuke - stock.adobe.com
NUP98 Rearrangements Linked to Poor Outcomes in AML

November 15th 2024

Tacrolimus | Image Credit: © MQ-Illustrations - stock.adobe.com
Tacrolimus Linked to Lower Acute GVHD Risk

November 7th 2024

Blood cells from blood marrow biopsy | image credit: Катерина Євтехова - stock.adobe.com
Patients With MDS Disagree With Physicians About Symptom Frequency

November 2nd 2024

More News

Scientists Unveil New Target to Stop Bortezomib Resistance in Patients With Multiple Myeloma
February 16th 2020

Scientists Unveil New Target to Stop Bortezomib Resistance in Patients With Multiple Myeloma

Jared Kaltwasser
Primary and acquired resistance to bortezomib can increase recurrence rates in patients with multiple myeloma. A new strategy could help reduce resistance.
Dr Adam Olszewski: Early Palliative Care Is Important and Beneficial for Patients With Blood Cancers
February 15th 2020

Dr Adam Olszewski: Early Palliative Care Is Important and Beneficial for Patients With Blood Cancers

Evidence is showing that early palliative care can be beneficial for patients with blood cancers, who receive very intense treatments that impact quality of life, said Adam Olszewski, MD, associate professor of medicine at The Warren Alpert Medical School of Brown University.
Early Study of Bendamustine, Carfilzomib Shows Encouraging Results
February 14th 2020

Early Study of Bendamustine, Carfilzomib Shows Encouraging Results

AJMC Staff
Researchers describe results of carfilizomib and bendamustine in a phase 1/2 study.
Daratumumab-Based Combination Regimen Submitted for FDA Approval in Relapsed/Refractory Multiple Myeloma
February 12th 2020

Daratumumab-Based Combination Regimen Submitted for FDA Approval in Relapsed/Refractory Multiple Myeloma

Matthew Gavidia
Based on positive data from the phase 3 CANDOR study presented at the 2019 American Society of Hematology Annual Meeting, Janssen announced yesterday the submission of a supplemental biologics license application to the FDA seeking approval of daratumumab in combination with carfilzomib and dexamethasone for relapsed/refractory multiple myeloma.
Dr Reona Sakemura Explains Why Certain Cancers Are More Susceptible to CAR T-Cell Therapy
February 11th 2020

Dr Reona Sakemura Explains Why Certain Cancers Are More Susceptible to CAR T-Cell Therapy

Bone marrow derived cancer-associated fibroblasts promote tumor progression which can alter a treatment's course, said Reona Sakemura, MD, PhD, postdoctoral researcher at the Mayo Clinic.
Dr C. Patrick Carroll on Barriers to Accessing Nonpharmacologic Treatments to SDC-Related Pain
February 8th 2020

Dr C. Patrick Carroll on Barriers to Accessing Nonpharmacologic Treatments to SDC-Related Pain

There is not a lot of evidence on how well nonpharmacologic treatments work to treat sickle cell disease–related pain, and it can be difficult to get people access to these treatments, said C. Patrick Carroll, MD, director of psychiatric services, Sickle Cell Center for Adults, associate professor of psychiatry, Johns Hopkins Medicine.
Dr Reona Sakemura Discusses Barriers to the Success of CAR T-Cell Therapies
February 4th 2020

Dr Reona Sakemura Discusses Barriers to the Success of CAR T-Cell Therapies

Toxicities like cytokine release syndrome, along with other factors, limit widespread use of CAR T-cell therapies, said Reona Sakemura, MD, PhD, postdoctoral researcher at the Mayo Clinic.
Proteasome Inhibitors Show Promise as Treatment for Multiple Myeloma
January 31st 2020

Proteasome Inhibitors Show Promise as Treatment for Multiple Myeloma

Maggie L. Shaw
Three proteasome inhibitors (PIs) are approved for patients with multiple myeloma (MM): Bortezomib, a first-in class PI, fights both newly diagnosed and relapsed/refractory MM (RRMM); carfilzomib, a next-generation PI, treats RRMM as both a monotherapy and in combination; and ixazomib, the first oral PI, treats RRMM in combination. PIs work by preventing the proteasomes in cancerous plasma cells from “recycling” what is essentially garbage protein.
Dr C. Patrick Carroll on Caution Using Opioids to Treat Sickle Cell Disease–Related Pain
January 30th 2020

Dr C. Patrick Carroll on Caution Using Opioids to Treat Sickle Cell Disease–Related Pain

Patients had never been particularly enthusiastic about using opioids to treat their pain related to sickle cell disease, but they are more cautious now, especially as they are often meet with suspicion of addiction, said C. Patrick Carroll, MD, director of psychiatric services, Sickle Cell Center for Adults, associate professor of psychiatry, Johns Hopkins Medicine.
Dr C. Patrick Carroll on Treating Pain for Patients With Sickle Cell Disease
January 29th 2020

Dr C. Patrick Carroll on Treating Pain for Patients With Sickle Cell Disease

Managing people with sickle cell disease and complex chronic pain is difficult and requires some trial and error, said C. Patrick Carroll, MD, director of psychiatric services, Sickle Cell Center for Adults, associate professor of psychiatry, Johns Hopkins Medicine.
ICER Releases Draft Evidence Report for Sickle Cell, Scoping Document for Hemophilia
January 25th 2020

ICER Releases Draft Evidence Report for Sickle Cell, Scoping Document for Hemophilia

Matthew Gavidia
The Institute for Clinical and Economic Review (ICER) published a draft evidence report on crizanlizumab (Adakveo), voxelotor (Oxbryta), and L-glutamine (Endari) for sickle cell disease, as well as a draft scoping document on valoctocogene roxaparvovec, an investigational gene therapy, and emicizumab (Helimbra) for hemophilia.
Site Logo
January 22nd 2020

Managing Vaso-Occlusive Crisis in Sickle Cell Disease: A Look at the Clinical and Economic Burden

https://www.pharmacytimes.org/on-demand/managing-vasoocclusive-crisis-in-sickle-cell-disease-a-look-at-the-clinical-and-economic-burden
Site Logo
January 21st 2020

Biosimilars at ASH 2019: Data on Truxima and Competitors for Eculizumab

Kelly Davio
Results for Truxima, recently launched in the United States, and complement inhibitors were presented at the 61st American Society of Hematology Annual Meeting and Exposition.
Site Logo
January 21st 2020

ASH 2019: Patient-Reported Outcomes, From MOST to FDA Clinical Reviews

Maggie L. Shaw
Symptom burden, functional ability, and quality of life are necessary considerations when treating hematologic malignancies in older patients.
Site Logo
January 21st 2020

ASH 2019: Real-World Evidence and Cost of Care

Maggie L. Shaw Mary Caffrey
Reviews of apixaban in active cancer, Medicare costs after CAR T-cell therapy, and the need for financial assistance for novel therapies.
Site Logo
January 20th 2020

CAR T-Cell Therapy and Beyond: UCART 19 and Anti-BCMA Therapy

Mary Caffrey
A pair of interviews on investigational therapies whose sponsors reported updates at the 61st American Society of Hematology Annual Meeting and Exposition: UCART19 from Servier and a revamped anti-BCMA therapy ide-cel from bluebird bio.
Site Logo
January 20th 2020

CAR T-Cell Therapy and Beyond: Off-the-Shelf Therapies Among Innovations at ASH 2019

Mary Caffrey
Coverage from the 61st American Society of Hematology Annual Meeting and Exposition in Orlando, Florida, featured results for allogeneic or "off the shelf" CAR T-cell treatments and bispecific antibodies.
PBSC Mobilization Yields Sufficient CD34+ Cell Counts in Patients With MM and Lymphoma, Study Finds
January 19th 2020

PBSC Mobilization Yields Sufficient CD34+ Cell Counts in Patients With MM and Lymphoma, Study Finds

Alison Rodriguez
A study identifying the different factors influencing peripheral blood hematopoietic stem cell (PBSC) mobilization and collection in multiple myeloma (MM) and lymphoma cases determined that PBSC mobilization yielded sufficient CD34+ cell counts in both patients with MM and lymphoma, but the failure rates were high.
Revolutionary Treatment for Sickle Cell Disease Shows Promise in Clinical Trial
January 17th 2020

Revolutionary Treatment for Sickle Cell Disease Shows Promise in Clinical Trial

Maggie L. Shaw
Sickle cell disease is the most common red blood cell disorder in the United States, having been diagnosed in approximately 100,000 African Americans alone. The lack of oxygen from sickle cell buildup can lead to acute pain crises, joint and organ damage, stroke, and reduced life expectancy.
Managing Sickle Cell Disease: Innovations, Limitations Within Evolving Standards of Care
January 16th 2020

Managing Sickle Cell Disease: Innovations, Limitations Within Evolving Standards of Care

Matthew Gavidia
In the evolving treatment landscape for sickle cell disease, current standards of treatment involve 4 drugs that have been FDA approved, with further innovations and limitations adding to the paradigm of care.
Dr Ruben Mesa on Fedratinib's Impact on Health-Related Quality of Life in Myelofibrosis
January 15th 2020

Dr Ruben Mesa on Fedratinib's Impact on Health-Related Quality of Life in Myelofibrosis

Research has shown that fedratinib favorably impacts health-related quality of life for patients with myelofibrosis across the board, said Ruben Mesa, MD, director of UT Health San Antonio MD Anderson Cancer Center.
Immunotherapy for Multiple Myeloma: A Report Outlining Currently Approved Monoclonal Antibody Treatments
January 15th 2020

Immunotherapy for Multiple Myeloma: A Report Outlining Currently Approved Monoclonal Antibody Treatments

Alison Rodriguez
Immunotherapy continues to be increasingly used for treating multiple myeloma (MM) with a recent report providing an overview of monoclonal antibodies (mAbs) currently approved for treating MM, as well as, compounds that are under investigation.
Dr C. Patrick Carroll on the Challenges of Treating Sickle Cell Disease–Related Pain With Opioids
January 11th 2020

Dr C. Patrick Carroll on the Challenges of Treating Sickle Cell Disease–Related Pain With Opioids

As a result of the opioid epidemic, there have been instances where it has been difficult to treat patients with pain related to their sickle cell disease because of new policies in place intended to curb addiction and overdoses, said C. Patrick Carroll, MD, director of psychiatric services, Sickle Cell Center for Adults, associate professor of psychiatry, Johns Hopkins Medicine.
Dr Abby Statler Discusses Restrictive Criteria Excluding Minority Patients From AML Trials
January 3rd 2020

Dr Abby Statler Discusses Restrictive Criteria Excluding Minority Patients From AML Trials

In research presented at the 61st American Society of Hematology Annual Meeting and Exposition, Abby Statler, PhD, MPH, MA, research associate, Cleveland Clinic, and her colleagues found that African Americans with acute myeloid leukemia (AML) may be excluded from clinical trials due to renal dysfunction, despite it having no impact on AML outcomes.
Data Show Fixed-Dose Daunorubicin Plus Cytarabine Leads to Fewer Inpatient Days for Patients With sAML
January 2nd 2020

Data Show Fixed-Dose Daunorubicin Plus Cytarabine Leads to Fewer Inpatient Days for Patients With sAML

Mary Caffrey
An executive with Jazz Pharmaceuticals said the ability to extend survival time in patients with secondary AML, and potentially offer them improved odds for transplant is an advance over traditional chemotherapy.
Dr C. Ola Landgren Discusses Identification of Smoldering Myeloma
December 25th 2019

Dr C. Ola Landgren Discusses Identification of Smoldering Myeloma

The terminology for smoldering myeloma has been around for decades, but more discussion over what it means and who it really applies to is needed, said C. Ola Landgren, MD, PhD, professor of medicine and chief of the Myeloma Service at Memorial Sloan Kettering Cancer.
Persistence of CAR T Cells Seen in "Next-Generation" Anti-BCMA Therapy, bluebird bio's Ide-cel
December 23rd 2019

Persistence of CAR T Cells Seen in "Next-Generation" Anti-BCMA Therapy, bluebird bio's Ide-cel

Mary Caffrey
The company presented updated phase 1 results for a revamped version of bb2121 that point to sustained responses for patients with relapsed/refractory multiple myeloma.
Leukemia Patients Treated With Anthracyclines Have Increased Risk of Heart Failure in Study
December 23rd 2019

Leukemia Patients Treated With Anthracyclines Have Increased Risk of Heart Failure in Study

Mary Caffrey
As more patients with cancer survive, the risk of cardiac complications due to the effects of therapies has become a concern to oncologists and cardiologists alike.
Unmet Needs and the Future of Myeloma
December 19th 2019

Unmet Needs and the Future of Myeloma

Maintenance Therapy and Relapse/Refractory Treatment
December 19th 2019

Maintenance Therapy and Relapse/Refractory Treatment

<1
...
456789101112
...
23>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo